Jeffrey B Woolsey, MD | |
2400 Hartman Ln, Springfield, OR 97477-1118 | |
(541) 334-3350 | |
(541) 284-5198 |
Full Name | Jeffrey B Woolsey |
---|---|
Gender | Male |
Speciality | Urology |
Experience | 18 Years |
Location | 2400 Hartman Ln, Springfield, Oregon |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063572238 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | MD26728 (Oregon) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mercy Medical Center | Roseburg, OR | Hospital |
Mckenzie-willamette Medical Center | Springfield, OR | Hospital |
Sacred Heart Medical Center - Riverbend | Springfield, OR | Hospital |
Peacehealth Cottage Grove Community Medical Center | Cottage grove, OR | Hospital |
Bay Area Hospital | Coos bay, OR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Oregon Urology Institute Pc | 6608766399 | 30 |
News Archive
Investigators at Brigham and Women's Hospital have developed a hydrogel patch that can adhere to tumors in a preclinical model of colon cancer, delivering a local, combination treatment as the elastic gel breaks down over time.
Recognition of the important role psychology has in the Freedom to Speak Up Review is welcomed by the British Psychological Society.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.
Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.
› Verified 3 days ago
Entity Name | Oregon Urology Institute Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801812078 PECOS PAC ID: 6608766399 Enrollment ID: O20040317000434 |
News Archive
Investigators at Brigham and Women's Hospital have developed a hydrogel patch that can adhere to tumors in a preclinical model of colon cancer, delivering a local, combination treatment as the elastic gel breaks down over time.
Recognition of the important role psychology has in the Freedom to Speak Up Review is welcomed by the British Psychological Society.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.
Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Jeffrey B Woolsey, MD 2400 Hartman Ln, Springfield, OR 97477-1118 Ph: (541) 334-3350 | Jeffrey B Woolsey, MD 2400 Hartman Ln, Springfield, OR 97477-1118 Ph: (541) 334-3350 |
News Archive
Investigators at Brigham and Women's Hospital have developed a hydrogel patch that can adhere to tumors in a preclinical model of colon cancer, delivering a local, combination treatment as the elastic gel breaks down over time.
Recognition of the important role psychology has in the Freedom to Speak Up Review is welcomed by the British Psychological Society.
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.
Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.
› Verified 3 days ago
Kevin Krughoff, Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-736-2934 | |
Dr. Jessica Catherine Lloyd, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln Ste 100, Springfield, OR 97477 Phone: 541-334-3350 | |
David S Dimarco, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
Christopher Charles Kyle, MD, MPH Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
Dawn M Bodell, DO Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 | |
David Esrig, Urology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hartman Ln, Springfield, OR 97477 Phone: 541-334-3350 Fax: 541-284-5198 |